RE:Buyout NumbersThe $137 m deal with Ipsen is contingent to getting MCNA FDA approved in US. So Ipsen is definitely looking to save that money and get it approved themselves. In my opinion, considering the company is worth $1/share plus you have big investors who invested at 40 c or more, a reasonable offer would be 50-80 cents a share but others have a smaller window, 15-40 cents. Either way, an easy double, from where it's at currently. Again this is my opinion, I could be completely wrong.